Prelude Therapeutics Incorporated
NASDAQ:PRLDBiotechnology
-$0.14 today
- Market cap
- $191.00M
- Beta
- 1.01
- P/E (TTM)
- -4.5
- EPS (TTM)
- -$0.94
Volume 0.23M
Average 0.38M
PRLD Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Prelude Therapeutics IncorporatedNASDAQ: PRLD
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development declines year over year
Q1 FY2026 research & development of $13.6M fell 52.8% year over year, behind the -33.8% change in trailing-twelve-month research & development. Sequentially, it fell 24.4% from the prior quarter. Over 3 fiscal years it compounded at +0.5% a year.
Context
- Research & development amounted to 776.8% of revenue in FY2025, down 908.9 pp from a year earlier.
- Research & development increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -52.8% toward the trailing-twelve-month pace of -33.8%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 94.3M USD
- Year-over-year change
- -20.1%
- 4-year CAGR
- +2.1%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 94.3M | -20.1% |
| FY2024 | 2024-12-31 | 118M | +14.1% |
| FY2023 | 2023-12-31 | 103.39M | +11.3% |
| FY2022 | 2022-12-31 | 92.89M | +7.0% |
| FY2021 | 2021-12-31 | 86.78M | — |
Research & Development vs competitors
How PRLD compares with its peers on the latest reported figures
- Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -33.8% is the lowest of 11, against a peer median of +6.7%.
- Research & development amounts to 473.0% of revenue for PRLD, versus a peer median of 696.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $10.68B USD | +22061.7% | +5.1% | — | |
| LTM Mar 2026 | $94.52M USD | -28.3% | +10.0% | 843.7% | |
| LTM Mar 2026 | $91.32M USD | -20.8% | -13.4% | 131.9% | |
| FY2025 | €83.61M EUR | -8.0% | +11.4% | 1865.0% | |
| LTM Mar 2026 | $82.1M USD | -9.4% | -6.8% | 290.9% | |
| LTM Mar 2026 | $79.09M USD | -33.8% | +0.5% | 473.0% | |
| LTM Mar 2026 | $76.25M USD | +21.5% | -5.1% | 550.2% | |
| LTM Mar 2026 | $62.37M USD | -24.6% | -10.1% | 27721.8% | |
| LTM Mar 2026 | $60.48M USD | +28.2% | +38.4% | 184.8% | |
| LTM Mar 2026 | $55.01M USD | +74.4% | +17.0% | 93235.6% | |
EPRXEupraxia Pharmaceuticals Inc. | LTM Mar 2026 | $27.18M USD | +72.6% | +29.4% | — |
| Peer median (excluding PRLD) | — | +6.7% | +7.5% | 696.9% | |
Competitors are the stored peer set for PRLD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 7M | 12.14M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 1.71M |
| Gross Profit | 0 | 0 | 0 | 7M | 10.43M |
| Gross Margin | — | — | — | 100.0% | 85.9% |
| Research & Development | 86.78M | 92.89M | 103.39M | 118M | 94.3M |
| Selling, General & Admin | 26.96M | 30.65M | 28.88M | 28.72M | 22.41M |
| Operating Expenses | 113.74M | 123.54M | 132.28M | 146.71M | 115M |
| Depreciation & Amortization | 915K | 1.32M | 1.17M | 1.77M | 1.71M |
| EBITDA | (110.78M) | (114.11M) | (120.66M) | (125.4M) | (97.79M) |
| EBITDA Margin | — | — | — | -1791.4% | -805.5% |
| Operating Income | (113.74M) | (123.54M) | (132.28M) | (139.71M) | (104.57M) |
| Operating Margin | — | — | — | -1995.9% | -861.3% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 2.04M | 8.1M | 10.44M | 12.54M | 5.07M |
| Income Before Tax | (111.69M) | (115.44M) | (121.83M) | (127.17M) | (99.5M) |
| Pre-Tax Margin | — | — | — | -1816.8% | -819.6% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (111.69M) | (115.44M) | (121.83M) | (127.17M) | (99.5M) |
| Net Margin | — | — | — | -1816.8% | -819.6% |
| EPS (Basic) | (2.33) | (2.27) | (2.02) | (1.68) | (1.29) |
| EPS (Diluted) | (2.33) | (2.27) | (2.02) | (1.68) | (1.29) |
| Weighted Avg Shares | 47.6M | 47.37M | 60.36M | 75.81M | 76.96M |
| Weighted Avg Shares (Diluted) | 47.6M | 47.37M | 60.36M | 75.81M | 76.96M |
Prelude Therapeutics Incorporated
NASDAQ:PRLD
Intrinsic Alpha fair value
Locked
Current Price
$3.30
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.